Core A (Administration) will have overall responsibility for: (A). Administration of the Program Project: "Experimental Therapeutics and BioMonitoring for Brain Tumors." This will include oversight of science, thematic goals, specimen allocation, personnel, finances and interactions. A project tracking system, interaction log and regular schedule of meetings and reviews insures productive high quality synergies between the three Projects and three Cores. These reviews and interactions include monthly web-based conferences, meetings with the Project and Core Leaders, interaction with Drs. Breakefield and Carter and Messer for thematic evaluation and definitions of end-points of study as well as consultations with the Internal Advisory committee members. Yearly review will be maintained by an External Advisory Board which will be convened. A portion of the Core B Biorepository will reside at the MGH under the aegis of Dr. Hochberg within Core A. (B). Neuropathologic oversight (Stemmer-Rachamimov) of veterinary studies (P1, Core C) and human studies as well as GBM cohorts resides within the Core A. (C). Statistical oversight resides in Core B (Messer) but local (Core A and Project 2,3) assistance is provided by Mrs. Muzikansky (Core A). The latter includes data sharing and pre-publication review. An experienced Scientific Program Manager will support Program Integration and Management by tracking Aims and agenda for monthly conferences.
This Core will provide the cohesion and oversight critical for co-ordinating a multi-institutional effort to evaluate therapeutic initiatives and biomarkers for gliomas. This will serve to increase the relevance and rigor of findings from this P01 to maximize its impact on therapy.
|Maguire, Casey A; Ramirez, Servio H; Merkel, Steven F et al. (2014) Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics 11:817-39|
|Nakashima, Hiroshi; Chiocca, E Antonio (2014) Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus. J Virol 88:345-53|
|Kaufmann, Johanna K; Chiocca, E Antonio (2014) Glioma virus therapies between bench and bedside. Neuro Oncol 16:334-51|
|Rajendran, Lawrence; Bali, Jitin; Barr, Maureen M et al. (2014) Emerging roles of extracellular vesicles in the nervous system. J Neurosci 34:15482-9|
|Hochberg, Fred H; Atai, Nadia A; Gonda, David et al. (2014) Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Rev Mol Diagn 14:439-52|
|Lai, Charles P; Mardini, Osama; Ericsson, Maria et al. (2014) Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8:483-94|
|Chiocca, E Antonio; Rabkin, Samuel D (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295-300|
|Redzic, Jasmina S; Balaj, Leonora; van der Vos, Kristan E et al. (2014) Extracellular RNA mediates and marks cancer progression. Semin Cancer Biol 28:14-23|
|Okemoto, Kazuo; Kasai, Kazue; Wagner, Benjamin et al. (2013) DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clin Cancer Res 19:5952-9|
|Atai, Nadia A; Balaj, Leonora; van Veen, Henk et al. (2013) Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J Neurooncol 115:343-51|
Showing the most recent 10 out of 140 publications